Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing …
Over the last 12 months, insiders at Brainstorm Cell Therapeutics Inc. have bought $283,114 and sold $22,069 worth of Brainstorm Cell Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Brainstorm Cell Therapeutics Inc. have bought $348,395 and sold $491,363 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lebovits Chaim (President & CEO) — $283,114.
The last purchase of 1,836 shares for transaction amount of $6,292 was made by Lebovits Chaim (President & CEO) on 2024‑10‑01.
2024-10-01 | President & CEO | 1,836 0.031% | $3.43 | $6,292 | -33.85% | |||
2024-09-30 | President & CEO | 22,000 0.0247% | $0.23 | $5,016 | -37.25% | |||
2024-07-19 | Sale | Chief Medical Officer | 63,000 0.0801% | $0.35 | $22,069 | -21.77% | ||
2024-05-28 | President & CEO | 15,000 0.0215% | $0.52 | $7,775 | -37.81% | |||
2024-05-22 | President & CEO | 25,000 0.0399% | $0.64 | $16,000 | -43.36% | |||
2024-05-21 | President & CEO | 25,000 0.0333% | $0.58 | $14,475 | -47.26% | |||
2024-05-13 | President & CEO | 10,000 0.0131% | $0.49 | $4,900 | -38.63% | |||
2024-05-11 | President & CEO | 10,000 0.015% | $0.47 | $4,665 | -20.07% | |||
2024-05-10 | President & CEO | 20,000 0.0298% | $0.47 | $9,300 | -26.17% | |||
2024-05-07 | President & CEO | 66,300 0.0971% | $0.37 | $24,816 | -7.97% | |||
2024-05-06 | President & CEO | 135,000 0.1982% | $0.38 | $50,666 | -9.45% | |||
2024-04-19 | President & CEO | 15,000 0.0214% | $0.52 | $7,799 | -35.28% | |||
2024-04-18 | President & CEO | 115,072 0.172% | $0.53 | $60,470 | -32.68% | |||
2024-04-17 | President & CEO | 130,000 0.1919% | $0.55 | $70,941 | -35.51% | |||
2023-09-01 | Co-Chief Executive Officer | 11,500 0.0277% | $1.77 | $20,402 | -78.57% | |||
2020-07-16 | Sale | 7,823 0.0252% | $13.47 | $105,351 | -62.10% | |||
2020-07-16 | EVP and COO | 5,000 0.0155% | $12.95 | $64,740 | -62.10% | |||
2020-07-15 | Sale | 18,430 0.06% | $13.12 | $241,715 | -60.36% | |||
2020-07-15 | director | 46,779 0.1507% | $12.99 | $607,659 | -60.36% | |||
2020-07-13 | Sale | 40,000 0.1354% | $13.52 | $540,952 | -59.56% |
Lebovits Chaim | President & CEO | 80960 1.5231% | $1.60 | 13 | 0 | |
ACCBT Corp. | 10 percent owner | 7075000 133.0986% | $1.60 | 5 | 0 | |
Abbhi Sankesh | director | 2164530 40.7203% | $1.60 | 1 | 0 | |
Lindborg Stacy | Co-Chief Executive Officer | 181500 3.4145% | $1.60 | 1 | 0 | <0.0001% |
ARBEL IRIT | director | 155833 2.9316% | $1.60 | 1 | 1 | <0.0001% |
The Vanguard Group | $791,140.00 | 1.76 | 1.4M | -1.57% | -$12,602.40 | <0.0001 | |
BlackRock | $276,315.00 | 0.62 | 489,313 | +4.92% | +$12,964.38 | <0.0001 | |
Geode Capital Management | $201,711.00 | 0.45 | 357,041 | 0% | +$0 | <0.0001 | |
Liberty Wealth Management Llc | $192,000.00 | 0.43 | 340,150 | 0% | +$0 | 0.05 | |
Weaver Consulting Group | $112,577.00 | 0.25 | 199,356 | 0% | +$0 | 0.05 |